Switch theme
Sign up to access all valuation multiples
Cawachi Ltd is a drug store operator based in Japan. The firm primarily sells pharmaceutical-related products to its customers. It also sells health foods, child care products, cosmetics, grocery, general food and confectionery through its retail outlets. The company operates over 300 stores across Japan.
1980
6.7K+
LTM Revenue n/a
LTM EBITDA n/a
$282M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cawachi has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Cawachi achieved revenue of $1.9B and an EBITDA of $76.4M.
Cawachi expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cawachi valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.9B | $1.9B | XXX | XXX | XXX |
| Gross Profit | $420M | $426M | XXX | XXX | XXX |
| Gross Margin | 22% | 22% | XXX | XXX | XXX |
| EBITDA | $72.9M | $76.4M | XXX | XXX | XXX |
| EBITDA Margin | 4% | 4% | XXX | XXX | XXX |
| Net Profit | $32.1M | $27.8M | XXX | XXX | XXX |
| Net Margin | 2% | 1% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Cawachi's stock price is JPY 2897 (or $19).
Cawachi has current market cap of JPY 64.7B (or $430M), and EV of JPY 42.4B (or $282M).
See Cawachi trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $282M | $430M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Cawachi has market cap of $430M and EV of $282M.
Cawachi's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Cawachi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Cawachi and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $282M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCawachi's NTM/LTM revenue growth is n/a
Cawachi's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Cawachi's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Cawachi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Cawachi and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 20% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Oriola | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cawachi acquired XXX companies to date.
Last acquisition by Cawachi was XXXXXXXX, XXXXX XXXXX XXXXXX . Cawachi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Cawachi founded? | Cawachi was founded in 1980. |
| Where is Cawachi headquartered? | Cawachi is headquartered in Japan. |
| How many employees does Cawachi have? | As of today, Cawachi has 6.7K+ employees. |
| Is Cawachi publicy listed? | Yes, Cawachi is a public company listed on TKS. |
| What is the stock symbol of Cawachi? | Cawachi trades under 2664 ticker. |
| When did Cawachi go public? | Cawachi went public in 2002. |
| Who are competitors of Cawachi? | Similar companies to Cawachi include e.g. MedPlus India, Pague Menos, Droga Raia, Redcare Pharmacy. |
| What is the current market cap of Cawachi? | Cawachi's current market cap is $430M |
| What is the current revenue growth of Cawachi? | Cawachi revenue growth between 2023 and 2024 was 1%. |
| Is Cawachi profitable? | Yes, Cawachi is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
